Open AccessCOMPUTER AIDED DRUG DESIGN: A PARADIGM SHIFT TO RATIONAL DRUG DESIGN (A CASE STUDY OF ALZHEIMER’S DRUG INTERPIRDINE FAILURE)
Author(s) -
Kalpana Virendra Singh,
Shobha Shouche,
Ramchander Merugu,
Jeeven S. Solanki
Publication year - 2020
Publication title -
international journal of engineering technologies and management research
Language(s) - English
Resource type - Journals
ISSN - 2454-1907
DOI - 10.29121/ijetmr.v4.i12.2017.585
Subject(s) - drug , drug discovery , clinical trial , computer aided , medicine , risk analysis (engineering) , drug development , process (computing) , computer science , pharmacology , bioinformatics , biology , programming language , operating system
Drug discovery and design is a tedious and lengthy process which takes enormous time, andwhen this process reaches it’s final stage that is the final stage of clinical trials 90% of thepromising drug candidates fail levying a huge financial burden of around $2-3bn on thedeveloper company. The drug failure not only incurs a financial loss to the company, but alsosmashes the hopes of the patients and families waiting for the successful approval of the drug.The scenario is even complicated when it comes to the drug approval for diseases likeAlzheimer’s. Computer aided drug design may help in the drug discovery process by slashingthe time required for searching the potential drug target through computer aided software andprograms. However the key to the success of the drug still lies in the understanding of themechanism of the cause of disease and prognosis. Computer aided drug design help in theselection and modification of leads out of number of hits available. The present study dealswith a case study of Intepridine an ambitious Axovant drug molecule which failed in the finalphase of clinical trials and was withdrawn from the market by Axovant the developer pharmacompany.